Pay in 4 interest-free payments of $6.21 Learn more
Ships within 48 hours · Estimated delivery Aug 9 - Aug 14
In this review, we summarize preclinical and clinical data from studies with FGF21 and FGF21 analogs, in the context of the pathophysiology of NASH and underlying metabolic diseases
(2019) 156:13451353.e4
Zepbound KwikPen onlysingle-dose vials and single-dose pens not covered
Efficacy and safety of canagliflozin as add-on therapy to a glucagon-like peptide-1 receptor agonist in Japanese patients with type 2 diabetes mellitus: a 52-week, open-label, phase IV study
Yin et al., 2019
The study is fully recruited and ongoing (84)
US$ 20.25
US$ 25.54
US$ 27.80
